CARDIFF ONCOLOGY, INC. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
CARDIFF ONCOLOGY, INC. (CRDF) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 0 shares for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-11-07.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2018-11-07
- CARDIFF ONCOLOGY, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2018-09-30 was 0.00 shares.
- CARDIFF ONCOLOGY, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2018-06-30 was 0.00 shares.
- CARDIFF ONCOLOGY, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2018-03-31 was 0.00 shares.
- CARDIFF ONCOLOGY, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2017-09-30 was 0.00 shares.
- CARDIFF ONCOLOGY, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2017 was 0.00 shares, a 100.00% decline from fiscal 2016.
- CARDIFF ONCOLOGY, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2016 was 106.42K shares, a 57.51% decline from fiscal 2015.
- CARDIFF ONCOLOGY, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2015 was 250.45K shares, a 50.12% increase from fiscal 2014.
- CARDIFF ONCOLOGY, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2014 was 166.83K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month |
|---|---|---|---|---|
| 2018-09-30 | 0.00 shares 10-Q · filed 2018-11-07 | 0.00 shares 10-Q · filed 2018-11-07 | ||
| 2018-06-30 | 0.00 shares 10-Q · filed 2018-08-03 | 0.00 shares 10-Q · filed 2018-08-03 | ||
| 2018-03-31 | 0.00 shares 10-Q · filed 2018-05-08 | |||
| 2017-12-31 | 0.00 shares 10-K · filed 2018-02-26 | |||
| 2017-09-30 | 0.00 shares 10-Q · filed 2018-11-07 | 0.00 shares 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | 0.00 shares 10-Q · filed 2018-08-03 | 0.00 shares 10-Q · filed 2018-08-03 | ||
| 2017-03-31 | 0.00 shares 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | 106.42K shares 10-K · filed 2018-02-26 | |||
| 2016-09-30 | 0.00 shares 10-Q · filed 2017-11-09 | 117.73K shares 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | 0.00 shares 10-Q · filed 2017-08-09 | 176.60K shares 10-Q · filed 2017-08-09 | ||
| 2016-03-31 | 353.19K shares 10-Q · filed 2017-05-10 | |||
| 2015-12-31 | 250.45K shares 10-K · filed 2017-03-15 | |||
| 2015-09-30 | 568.02K shares 10-Q · filed 2016-11-09 | 189.34K shares 10-Q · filed 2016-11-09 | ||
| 2015-06-30 | 0.00 shares 10-Q · filed 2016-08-04 | 0.00 shares 10-Q · filed 2016-08-04 | ||
| 2015-03-31 | 0.00 shares 10-Q · filed 2016-05-10 | |||
| 2014-12-31 | 166.83K shares 10-K · filed 2017-03-15 | |||
| 2014-09-30 | 0.00 shares 10-Q · filed 2015-11-09 | 109.99K shares 10-Q · filed 2015-11-09 | ||
| 2014-06-30 | 329.98K shares 10-Q · filed 2015-08-10 | 164.99K shares 10-Q · filed 2015-08-10 | ||
| 2013-12-31 | 0.00 shares 10-K · filed 2016-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |